Delta9-Tetrahydrocannabinol
Complex Regional Pain Syndrome
Explore 4 assets in Complex Regional Pain Syndrome →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Ludwig-Maximilians - University of Munich
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00377468CT.gov Effect of Delta-9-Tetrahydrocannabinol on the Prevention of Chronic Pain in Patients With Acute CRPS (ETIC-Study) | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Complex Regional Pain Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Delta9-Tetrahydrocannabinol (this asset) | Ludwig-Maximilians - University of Munich | P2 | CCC · 53 |
| Lidocaine | Endo USA Inc., a Keenova Therapeutics Company | P4 | BB |
| Ibuprofen | Amgen | P3 | BB |
| Gabapentin | Endo USA Inc., a Keenova Therapeutics Company | P4 | BB |
| Naltrexone | Hospital for Special Surgery, New York | P4 | BB |
| Fentanyl | Janssen Pharmaceutical K.K. | P3 | BB |
| Axs-02 | Axsome Therapeutics, Inc. | P3 | B |
| Cetuximab | Sorlandet Hospital HF | P2 | B |
| Soticlestat | Millennium Pharmaceuticals, Inc. | P2 | CCC |
+11 more in the Complex Regional Pain Syndrome cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Delta9-Tetrahydrocannabinol in Complex Regional Pain Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/delta9-tetrahydrocannabinol-complex-regional-pain-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →